UNC0646

Catalog No.S7020 Batch:S702001

Technical Data

Formula	C₃₆H₅₉N₇O₂
Molecular Weight	621.9	CAS No.	1320288-17-2
Solubility (25°C)*	In vitro	Ethanol	50 mg/mL (80.39 mM)
		DMSO	33 mg/mL (53.06 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

UNC0646 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM , respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.

Targets

G9a ^[1] (Cell-free assay)	GLP ^[1] (Cell-free assay)
6 nM	15 nM

In vitro

UNC0646 is a novel G9a inhibitor with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity. UNC0646 has high in vitro potency versus G9a and improved lipophilicity, are highly potent (IC50 < 0.06 μM) in reducing H3K9me2 levels in MDA-MB-231 cells and has low cell toxicity.^[1]

In vivo

Due to its water insolubility, the in vivo efficacy of UNC0646 is not satisfactory. Nanodiamonds (NDs) are utilized as a drug delivery platform to improve in vivo delivery of this small-molecule inhibitor. ND-UNC0646 complexes can be rapidly synthesized by physical adsorption, meanwhile possessing favorable drug delivery properties and is able to improve the dispersibility of UNC0646 in water, therefore making it amenable for intravenous administration. The release profile of UNC0646 from NDUNC0646 is demonstrated to be pH-responsive. Moreover, ND-UNC0646 maintains the biological functionality of UNC0646, with higher efficacy in reducing H3K9 methylation as well as enhanced invasion suppressive effects. Most importantly, increased in vivo efficacy is demonstrated using an orthotopic Hepatocellular carcinoma (HCC) mouse model, which paves the way of translating this small-molecule inhibitor toward HCC treatment.^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines MDA-MB-231 cells Concentrations various concentrations Incubation Time 48 h Method Cells are seeded at 5–10 thousand cells in black walled 96 well plates and exposed to various inhibitor concentrations for 48h. The media is removed and 2% Formaldehyde in PBS for fixation is added for 15 min. After five washes with 0.1% Triton X100 in PBS, cells are blocked for 1h with 1% BSA in PBS. Three out of four replicates are exposed to the primary H3K9me2 antibody for 2 h. One replicate is reserved for the background control. The wells are washed five times with 0.1% Tween 20 in PBS, then secondary IR800 conjugated antibody and nucleic acid-intercalating dye, DRAQ5 added for 1 h. After 5 washes with 0.1% Tween 20 PBS, the plates are read on an Odyssey scanner at 800 nm (H3K9me2 signal) and 700 nm (DRAQ5 signal).
Animal Study:^{^[2]}	Animal Models 8 week-old female immunodeficient NOD/SCID mice Dosages 1 mg/kg, 2 mg/kg Administration IV (via tail vein)

Cell Assay:^{^[1]}

Cell lines
MDA-MB-231 cells
Concentrations
various concentrations
Incubation Time
48 h
Method
Cells are seeded at 5–10 thousand cells in black walled 96 well plates and exposed to various inhibitor concentrations for 48h. The media is removed and 2% Formaldehyde in PBS for fixation is added for 15 min. After five washes with 0.1% Triton X100 in PBS, cells are blocked for 1h with 1% BSA in PBS. Three out of four replicates are exposed to the primary H3K9me2 antibody for 2 h. One replicate is reserved for the background control. The wells are washed five times with 0.1% Tween 20 in PBS, then secondary IR800 conjugated antibody and nucleic acid-intercalating dye, DRAQ5 added for 1 h. After 5 washes with 0.1% Tween 20 PBS, the plates are read on an Odyssey scanner at 800 nm (H3K9me2 signal) and 700 nm (DRAQ5 signal).

Animal Study:^{^[2]}

Animal Models
8 week-old female immunodeficient NOD/SCID mice
Dosages
1 mg/kg, 2 mg/kg
Administration
IV (via tail vein)

References

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.